1. Home
  2. KRUS vs DRUG Comparison

KRUS vs DRUG Comparison

Compare KRUS & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kura Sushi USA Inc.

KRUS

Kura Sushi USA Inc.

HOLD

Current Price

$57.52

Market Cap

602.8M

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$66.90

Market Cap

707.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRUS
DRUG
Founded
2008
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Pharmaceuticals and Biotechnology
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
602.8M
707.1M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
KRUS
DRUG
Price
$57.52
$66.90
Analyst Decision
Buy
Strong Buy
Analyst Count
9
6
Target Price
$81.11
$129.25
AVG Volume (30 Days)
453.4K
432.3K
Earning Date
04-07-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
79.75
N/A
EPS
N/A
N/A
Revenue
$282,763,000.00
N/A
Revenue This Year
$20.50
N/A
Revenue Next Year
$20.68
N/A
P/E Ratio
N/A
N/A
Revenue Growth
18.88
N/A
52 Week Low
$42.62
$24.18
52 Week High
$95.98
$123.75

Technical Indicators

Market Signals
Indicator
KRUS
DRUG
Relative Strength Index (RSI) 60.27 45.96
Support Level $53.62 $49.47
Resistance Level $64.22 $70.23
Average True Range (ATR) 3.33 4.41
MACD 1.27 1.24
Stochastic Oscillator 79.65 61.06

Price Performance

Historical Comparison
KRUS
DRUG

About KRUS Kura Sushi USA Inc.

Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: